check_circleStudy Completed

Hypertension

Bayer Identifier:

14881

ClinicalTrials.gov Identifier:

NCT01211171

EudraCT Number:

Not Available

EU CT Number:

Not Available
COugh among hypertensive patients treated with telmisartan, who had to stop previoUs ACE-I treatment due to couGH in Poland

Trial purpose

In the light of ONTARGET and TRANSCEND studies results, it would be interesting to investigate the real-life telmisartan treatment tolerability. It is well known and accepted that the Real-life setting is much more adequate to reflect the antihypertensive and safety properties of the drug in comparison to the organized and scheduled setting of the clinical trial. Because there are not much data on the cough in relation to telmisartan, therefore it would we worth to observe the cough frequency and general treatment tolerance in patients treated with telmisartan, who had to stop their previous ACE-I treatment due to cough.

Key Participants Requirements

Sex

Both

Age

18 - N/A
  • - hypertension
    - age > 18
    - ACE-I related cough
  • - Current treatment with telmisartan
    - Cholestatic disorders and severe hepatic failure
    - Allergy to telmisartan
    - Pregnancy and lactation period

Trial summary

Enrollment Goal
2498
Trial Dates
May 2009 - December 2009
Phase
N/A
Could I Receive a placebo
No
Products
Kinzal/Pritor (Telmisartan, BAY68-9291)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Many Locations, Poland

Primary Outcome

  • Cough frequency among telmisartan treated patients, who had to stop their previous ACE-I treatment due to cough
    date_rangeTime Frame:
    4 months after initiation
    enhanced_encryption
    Safety Issue:
    Yes

Secondary Outcome

  • General tolerability and safety of telmisartan treatment among patients, who had to stop their previous ACE-I treatment due to cough
    date_rangeTime Frame:
    4 months after initiation
    enhanced_encryption
    Safety Issue:
    Yes

Trial design

COugh among hypertensive patients treated with telmisartan, who had to stop previoUs ACE-I treatment due to couGH
Trial Type
Observational
Intervention Type
Drug
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to Bayer Healthcare products.